Jaguar Animal Health (NASDAQ:JAGX) Releases Quarterly Earnings Results, Beats Expectations By $3.90 EPS

Jaguar Animal Health (NASDAQ:JAGX) released its earnings results on Tuesday. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.26) by $3.90, FiscalAI reports. The company had revenue of $3.24 million during the quarter, compared to analyst estimates of $4.21 million. Jaguar Animal Health had a negative return on equity of 1,194.94% and a negative net margin of 341.90%.

Jaguar Animal Health Trading Up 2.5%

NASDAQ:JAGX opened at $0.41 on Tuesday. The company has a market cap of $1.53 million, a P/E ratio of -0.01 and a beta of 0.27. The stock’s fifty day moving average price is $0.57 and its two-hundred day moving average price is $1.18. Jaguar Animal Health has a 1 year low of $0.31 and a 1 year high of $15.48. The company has a debt-to-equity ratio of 4.08, a current ratio of 0.81 and a quick ratio of 0.52.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Thursday, January 22nd. Wall Street Zen lowered Jaguar Animal Health to a “strong sell” rating in a report on Friday, January 23rd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $60.00.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.